First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

相似书籍

• Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
  由: George W Rutherford, et al.
  出版: (2016-01-01)
• Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial
  由: Aboulker, J, et al.
  出版: (2002)
• Lipidic strategy for improving bioavailability of nucleoside HIV reverse transcriptase inhibitor
  由: N. S. Shastina, et al.
  出版: (2011-04-01)
• Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review
  由: Tatevik Balayan, et al.
  出版: (2017-01-01)
• Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
  由: A. V. Kravchenko, et al.
  出版: (2018-07-01)